A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.
Lieve Adriaens
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Kyriakos P. Papadopoulos
Consultant or Advisory Role - Regeneron
Research Funding - Regeneron
Donna M. Graham
No relevant relationships to disclose
Amita Patnaik
Research Funding - Regeneron
Albiruni R.A. Razak
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Regeneron (U); Sanofi (U)
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Drew Warren Rasco
Research Funding - Regeneron
Pamela Trail
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Carrie M. Brownstein
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron
Israel Lowy
Employment or Leadership Position - Regeneron
Stock Ownership - Regeneron